MA
Veradermics, Incorporated
MANE · NYSE
$103.88 +5.45% (+$5.37)
1M -11.05%
Piotroski F-Score Weak
3/9Valuation
-
N/A P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A Debt/Assets N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
59 /100
Moderate Beta 1.23x
Profitable years N/A
Rev. volatility N/A
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MANE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Reid Waldman
Employees
37
Headquarters
New Haven
Upcoming events
10 NOV
Earnings
Upcoming earnings report